118 related articles for article (PubMed ID: 38853277)
21. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer.
Zhang Q; Wang J; Qiao H; Huyan L; Liu B; Li C; Jiang J; Zhao F; Wang H; Yan J
J Cell Mol Med; 2021 May; 25(9):4395-4407. PubMed ID: 33797839
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.
Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
[TBL] [Abstract][Full Text] [Related]
23. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
24. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
25. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells.
Saydaminova K; Strauss R; Xie M; Bartek J; Richter M; van Rensburg R; Drescher C; Ehrhardt A; Ding S; Lieber A
Cancer Biol Ther; 2016 Oct; 17(10):1079-1088. PubMed ID: 27574825
[TBL] [Abstract][Full Text] [Related]
26. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
27. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
29. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
30. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract][Full Text] [Related]
31. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
[TBL] [Abstract][Full Text] [Related]
32. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
33. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
34. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance.
Lee JH; Suh JH; Kang HJ; Choi SY; Jung SW; Lee-Kwon W; Park SA; Kim H; Ye BJ; Yoo EJ; Jeong GW; Park NH; Kwon HM
EBioMedicine; 2020 Aug; 58():102926. PubMed ID: 32739873
[TBL] [Abstract][Full Text] [Related]
35. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
36. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.
Farrand L; Kim JY; Byun S; Im-aram A; Lee J; Suh JY; Lee KW; Lee HJ; Tsang BK
J Biol Chem; 2014 Jan; 289(3):1723-31. PubMed ID: 24247248
[TBL] [Abstract][Full Text] [Related]
37. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
38. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
Sun H; Wang H; Wang X; Aoki Y; Wang X; Yang Y; Cheng X; Wang Z; Wang X
Theranostics; 2020; 10(15):6928-6945. PubMed ID: 32550913
[No Abstract] [Full Text] [Related]
39. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
40. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]